FEZF1 and neoplasm: Accumulating evidences have revealed that FEZF1-AS1 was abnormal expressed in tumor tissues and cells, and showed oncogenic effects on liver cancer (Gong et al. 2018), ovarian cancer (Zhao et al. 2018), and osteosarcoma (Zhou et al. 2018).